TY - Jour T1 - 儿童在线哮喘管理是经济高效的JF - 欧洲呼吸杂志Jo - Eur Respir J Do - 10.1183/13993003.01413-2017 VL - 50是 - 4 SP - 1701413 Au - van Den WijngaArt,Lara S. Au- Kievit,Wietske Au - Roukema,Jolt Au-Boehmer,Annemie L. Au - Brouwer,Marianne L. Au - Hugen,Cindy A.c. Au - Niers,Laetitia e.Mu - Sprij,Arwen J. Au - Rikkers-Mutsaerts,Eleonora R.v.m.Au - Rottier,Bart L. Au - Verhaak,Chris M. Au - Pijnenburg,MariëlleW.Au - Merkus,Peter J.F.M.Y1 - 2017/10/01 UR - //www.qdcxjkg.com/content/50/4/1701413.Abstract n2 - eHealth干预措施被提出为改善健康结果并降低医疗保健费用的吸引力方法[1-3]。然而,eHealth干预的发展与高成本有关,并且这种投资需要通过增加的临床效果和相关成本节约来平衡。遗憾的是,关于健康改善的eHealth的有效性的坚实证据仍然有限[2-5],就是有关成本效益的证据。这会导致eHealth的有效性的不确定性,并构成日常实践中成功实施的障碍[6,7]。因此,有必要评估效果和成本效益,以说服其增加值的同事和政策制定者。儿童的哮喘管理能否(部分)替代常规门诊访问,并且具有成本效益http://ow.ly/oabk30f7sre作者角色:彼得梅尔库斯;Pijnenburg,Mariëlle; Verhaak, Chris designed the study and obtained funding. van den Wijngaart, Lara; Roukema, Jolt; Boehmer, Annemie; Brouwer, Marianne; Verhaak, Chris; Niers, Laetitia; Sprij, Arwen; Rikkers-Mutsaerts, Eleonora; Rottier, Bart; Pijnenburg, Mariëlle; Merkus, Peter all participated as investigators, recruited patients and performed treatments. van den Wijngaart, Lara carried out the analyses. Kievit, Wietske conducted the cost-effectiveness analysis. van den Wijngaart, Lara; Kievit, Wietske; Roukema, Jolt; Merkus, Peter operated as the writing committee and drafted the manuscript until it reached its final form. All authors commented on the manuscript and its revisions. Merkus, Peter is the guarantor of the study. Ethical approval: This study was approved by all local ethics committees. All participants provided written informed consent. Data sharing: Patient-level data are available on reasonable request from the corresponding author. Patient consent was not obtained but the data presented are anonymised and risk of identification is absent. Transparency declaration: The lead author affirms that this manuscript is an honest, accurate and transparent account of the study being reported, that no important aspects of the study have been omitted, and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. Prior presentations: Results of this randomised controlled trial were presented at the Congress of the European Respiratory Society (Amsterdam, 2015). Results of the cost-effectiveness analysis were presented at the Congress of International Paediatric Pulmonology (Naples, 2016). Thanks: We are grateful to all the participating children and parents for their contribution to this study, as well as collaborating paediatricians and Sintnicolaas, Coosje (Radboud University Medical Centre, Amalia Children’s Hospital, Department of Paediatric Pulmonology, Nijmegen, The Netherlands); Stevens, Petra (Canisius Wilhelmina Hospital, Department of Paediatrics, Nijmegen, The Netherlands); Verwaal, Mariël (Maasstad Hospital, Department of Paediatrics, Rotterdam, The Netherlands); Bolder, Carola (Maxima Medical Centre, Department of Paediatrics, Veldhoven, The Netherlands); Winters, Ans (Leiden University Medical Centre, Department of Paediatric Pulmonology, Leiden, The Netherlands); Mulder, Ineke and van Baak, Christine (both Haga Hospital, Juliana Children’s Hospital, Department of Paediatric Pulmonology, The Hague, The Netherlands); Spierings, Magda and Hiddinga, Jantine (both Erasmus Medical Centre, Sophia Children’s Hospital and Kinderhaven/Havenziekenhuis, Department of Paediatric Pulmonology, Rotterdam, The Netherlands) for their enthusiasm and their efforts in recruiting and monitoring the patients. We acknowledge Hop, Wim (Erasmus Medical Centre, Department of Biostatistics, Rotterdam, The Netherlands) and Moll, Henriëtte (Erasmus Medical Centre, Sophia Children’s Hospital, Department of Paediatrics, Rotterdam, The Netherlands) for performing the interim safety analysis and also commemorate van Gent, Rene (Maxima Medical Centre, Department of Paediatrics, Veldhoven, The Netherlands) and thank him for his contributions to this study. ER -